42.95
0.24%
-0.0623
Crinetics Pharmaceuticals Inc stock is currently priced at $42.95, with a 24-hour trading volume of 111.87K.
It has seen a -0.24% decreased in the last 24 hours and a -5.03% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $43.47 pivot point. If it approaches the $42.41 support level, significant changes may occur.
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Crinetics Pharmaceuticals Inc (CRNX) Revenue 2024
CRNX reported a revenue (TTM) of $4.72 million for the quarter ending September 30, 2023, a -7.52% decline year-over-year.
Crinetics Pharmaceuticals Inc (CRNX) Net Income 2024
CRNX net income (TTM) was -$214.53 million for the quarter ending December 31, 2023, a -30.88% decrease year-over-year.
Crinetics Pharmaceuticals Inc (CRNX) Cash Flow 2024
CRNX recorded a free cash flow (TTM) of -$171.00 million for the quarter ending December 31, 2023, a -46.32% decrease year-over-year.
Crinetics Pharmaceuticals Inc (CRNX) Earnings per Share 2024
CRNX earnings per share (TTM) was -$3.70 for the quarter ending December 31, 2023, a -17.09% decline year-over-year.
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Struthers Richard Scott | President & CEO |
Apr 15 '24 |
Option Exercise |
1.91 |
20,000 |
38,200 |
257,835 |
Pizzuti Dana | Chief Med and Dev Officer |
Apr 15 '24 |
Sale |
44.47 |
14,375 |
639,256 |
27,786 |
Struthers Richard Scott | President & CEO |
Apr 04 '24 |
Option Exercise |
9.28 |
40,951 |
380,025 |
278,786 |
Struthers Richard Scott | President & CEO |
Apr 04 '24 |
Sale |
49.17 |
40,951 |
2,013,561 |
237,835 |
Okey Stephanie | Director |
Mar 28 '24 |
Option Exercise |
18.29 |
17,500 |
320,075 |
23,500 |
Okey Stephanie | Director |
Mar 28 '24 |
Sale |
46.38 |
17,500 |
811,650 |
6,000 |
Knight Jeff E. | Chief Operating Officer |
Mar 22 '24 |
Option Exercise |
23.98 |
30,000 |
719,400 |
84,939 |
Knight Jeff E. | Chief Operating Officer |
Mar 22 '24 |
Sale |
44.31 |
32,359 |
1,433,675 |
52,580 |
Fust Matthew K | Director |
Mar 20 '24 |
Option Exercise |
20.92 |
60,000 |
1,254,975 |
36,036 |
Pizzuti Dana | Chief Med and Dev Officer |
Mar 20 '24 |
Option Exercise |
16.89 |
14,375 |
242,794 |
38,500 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Zacks Investment Research
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Zacks Investment Research
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Zacks Investment Research
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Benzinga
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):